ArticleCancer immunology, immunotherapy : CII2026
Transcriptomic landscape of peripheral T cells following CAR-T cell therapy in diffuse large B cell lymphoma.
Article in Cancer immunology, immunotherapy : CII, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundCAR-T cell therapy has improved outcomes in relapsed/refractory large B cell lymphoma (LBCL), yet responses remain variable; baseline endogenous T cell state and post-infusion CAR-T differentiation may contribute to this heterogeneity, but the underlying transcriptional programs are incompletely defined.
methodsWe performed RNA-sequencing of CD3⁺ T cells from 26 LBCL patients at two time points-pre-apheresis (PA; n = 23) and day 14 post-infusion (D14; n = 9)-and applied differential expression, gene set enrichment analysis (GSEA), and gene regulatory network inference. RESULTS/
interpretationIn PA T cells, we identified 320 differentially expressed genes enriched for immune-related programs (TCR signaling, T cell differentiation, IL-2-related signaling, TCR regulation of apoptosis and misregulation of cancer) and signatures consistent with immune dysfunction. Unsupervised clustering defined two LBCL T cell expression profiles, which were strongly associated with early disease progression (91% vs 16%; P < 0.001), supporting a hyperactivated yet progressively dysfunctional T cell state that may compromise CAR-T fitness and persistence. At the pathway level, GSEA in LBCL PA T cells showed enrichment of PI3K/AKT/mTOR and MYC target programs together with apoptosis-related signatures.
conclusionsTranscriptomic heterogeneity in endogenous T cells is strongly linked to early post-CAR-T progression and may inform strategies to optimize CAR-T persistence and efficacy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.